Viking Therapeutics Inc. (VKTX)
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
Could Viking Therapeutics Become the Next Novo Nordisk?
Viking Therapeutics has a high valuation for a company with no sales. Novo Nordisk is competing in the same market, and that market is growing rapidly.
Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma
Viking Therapeutics has a powerful weight loss candidate in late-stage trials. Zealand Pharma has a handful of programs and a powerful collaborator.
The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.
The upstart biotech just reported its Q2 earnings -- and investors were pleased. All of its programs are proceeding according to plan, and it isn't spending much.
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Artificial intelligence (AI) chip leader Nvidia has soared 126% so far this year -- but this biotech stock has advanced even more. This biotech player is targeting a market that could be worth $100 billion by the end of the decade.
Is Viking Therapeutics a Millionaire-Maker Stock?
Viking is developing drug candidates in an area of high interest and growth: weight loss. The company is launching a phase 3 clinical trial for its first weight loss candidate.
Why Viking's Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks
Eli Lilly (LLY) and Novo Nordisk (NVO) shares lost ground, while shares of drugmaker Viking Therapeutics (VKTX) soared in intraday trading Thursday after the company reported advances in trials of its weight-loss drugs that could challenge the dominance of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.
Viking Therapeutics: Pharma Stock Soars on Positive Earnings
Viking Therapeutics NASDAQ: VKTX is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and the Viking Therapeutics' analyst community.
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
Why Viking Therapeutics Stock Is Skyrocketing Today
Viking Therapeutics plans to advance its obesity drug VK2735 into late-stage clinical testing. VK2735 could be a formidable rival to Lilly's Zepbound and Novo Nordisk's Wegovy if it's approved.
Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial
Shares of Viking Therapeutics jumped on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. It brings the drugmaker one step closer to joining the highly popular market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade.
Viking Therapeutics (VKTX) Stock Pops on Plans to Start Late-Stage Weight Loss Drug Trials
Viking Therapeutics (NASDAQ: VKTX ) stock is heading higher on Thursday as the clinical-stage biopharmaceutical company prepares to start another trial for its weight loss drug. Viking Therapeutics says that it's ready to progress subcutaneous VK2735 into a Phase 3 clinical trial as a treatment for obesity and other metabolic disorders.
